These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30762880)

  • 41. PD-1 blockade potentially enhances adoptive cytotoxic T cell potency in a human acute myeloid leukaemia animal model.
    Deng R; Fan FY; Yi H; Liu F; He GC; Sun HP; Su Y
    Hematology; 2018 Dec; 23(10):740-746. PubMed ID: 29962321
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
    Martinez M; Moon EK
    Front Immunol; 2019; 10():128. PubMed ID: 30804938
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
    Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
    J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Making CAR T Cells a Solid Option for Solid Tumors.
    Schmidts A; Maus MV
    Front Immunol; 2018; 9():2593. PubMed ID: 30467505
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.
    O'Hear C; Heiber JF; Schubert I; Fey G; Geiger TL
    Haematologica; 2015 Mar; 100(3):336-44. PubMed ID: 25480499
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chimeric antigen receptor T cell therapy in AML: How close are we?
    Gill S
    Best Pract Res Clin Haematol; 2016 Dec; 29(4):329-333. PubMed ID: 27890255
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Exploiting epigenetically mediated changes: Acute myeloid leukemia, leukemia stem cells and the bone marrow microenvironment.
    Kogan AA; Lapidus RG; Baer MR; Rassool FV
    Adv Cancer Res; 2019; 141():213-253. PubMed ID: 30691684
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Co-op CARs for targeting acute myeloid leukemia.
    Kondo T; Taylor N
    Cancer Cell; 2023 Nov; 41(11):1841-1843. PubMed ID: 37832553
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens.
    Greiner J; Döhner H; Schmitt M
    Haematologica; 2006 Dec; 91(12):1653-61. PubMed ID: 17145602
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The progress and current status of immunotherapy in acute myeloid leukemia.
    Yang D; Zhang X; Zhang X; Xu Y
    Ann Hematol; 2017 Dec; 96(12):1965-1982. PubMed ID: 29080982
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
    Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
    Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Circulating exosomes carrying an immunosuppressive cargo interfere with cellular immunotherapy in acute myeloid leukemia.
    Hong CS; Sharma P; Yerneni SS; Simms P; Jackson EK; Whiteside TL; Boyiadzis M
    Sci Rep; 2017 Oct; 7(1):14684. PubMed ID: 29089618
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
    Zolov SN; Rietberg SP; Bonifant CL
    Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
    Singh N; Frey NV; Grupp SA; Maude SL
    Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adoptive T cell therapy: An overview of obstacles and opportunities.
    Baruch EN; Berg AL; Besser MJ; Schachter J; Markel G
    Cancer; 2017 Jun; 123(S11):2154-2162. PubMed ID: 28543698
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
    Marcus A; Eshhar Z
    Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New approaches for the immunotherapy of acute myeloid leukemia.
    Geiger TL; Rubnitz JE
    Discov Med; 2015 Apr; 19(105):275-84. PubMed ID: 25977190
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype.
    Li S; Tao Z; Xu Y; Liu J; An N; Wang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
    Hum Gene Ther; 2018 May; 29(5):626-639. PubMed ID: 29409351
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunotherapy of acute myeloid leukaemia: development of a whole cell vaccine.
    Cheuk AT; Guinn BA
    Front Biosci; 2008 Jan; 13():2022-9. PubMed ID: 17981688
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors.
    Damiani D; Tiribelli M; Raspadori D; Sirianni S; Meneghel A; Cavalllin M; Michelutti A; Toffoletti E; Geromin A; Simeone E; Bocchia M; Fanin R
    Oncotarget; 2015 Oct; 6(30):30212-21. PubMed ID: 26338961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.